Human medicines European public assessment report EPAR Inflectra infliximab...
Human medicines European public assessment report EPAR Inflectra infliximab Arthritis PsoriaticSpondylitis AnkylosingColitis UlcerativePsoriasisCrohn DiseaseArthritis Rheumatoid Date of authorisation...
View ArticleDDW 2019 New Study Shows SonarMD Lowers Cost of Managing Crohns Disease
When people with Crohns disease worked together with their gastroenterologists to detect and address worsening symptoms sooner using SonarMDs care coordination solution they were more likely to stay...
View ArticleSetPoint Medical Reports New Data Demonstrating its Bioelectronic Medicine...
VALENCIA Calif. May 20 2019 GLOBE NEWSWIRE SetPoint Medical a clinicalstage bioelectronic medicine company developing therapy for chronic autoimmune diseases today announced new positive clinical data...
View ArticleLilly Advances IL23 Gastroenterology Ambitions With Mirikizumab In Crohn&39;s...
The company reported positive Phase II results and will move its potential fourthtomarket IL23 inhibitor into Phase III in Crohn&39;s...&160;&160;&160;
View ArticleMerck Buys Peloton On Eve Of IPO Expands Kidney Cancer Portfolio
Investors in Peloton which has the only clinicalstage HIF2 inhibitor will get back 3.5 times the $304m in venture capital...&160;&160;&160;&160;
View ArticleChugai To Plow $1bn Into New Core R&D Site
Japanese firm unveils major restructuring of R&D sites in Japan through a new $1bn core lab set to open in...&160;&160;&160;&160;
View ArticleChugai To Plough $1bn Into New Core R&D Site
Japanese firm unveils major restructuring of R&D sites in Japan through a new $1bn core lab set to open in...&160;&160;&160;&160;
View ArticleTakeda scores Japanese Entyvio approval in Crohn's disease
Takeda has announced that Japans drug regulator the Ministry of Health Labour and Welfare MHLW has approved Entyvio vedolizumab in the treatment of moderately to severely active Crohns disease CD.The...
View ArticleLilly drug scores in Phase 2 Crohn's study
After 12 weeks of treatment three doses of Lilly&39;s mirikizumab beat placebo on the study&39;s primary endpoint setting it up for latestage testing.
View ArticleCombined Immunosuppression in Adults >60 With Crohn's Disease
Older adults with Crohn's disease have tended to be treated less aggressively than younger patients. Is a treatment strategy of combined immunosuppression safe and effective in those 60 and over...
View ArticleLillys Mirikizumab succeeds in phase 2 study in Crohns disease
Patients treated with mirikizumab in the SERENITY Phase 2 study achieved significant reductions in clinical and endoscopic measures of disease activity at 12 weeks compared to placebo. The The post...
View ArticleLilly moves Crohn's drug into phase 3 faces safety setback in Japan
Eli Lilly has had a mixed few days posting promising trial results for midstage Crohns disease drug mirikizumab undercutting a key insulin from Sanofi in the US but facing safety concerns over a new...
View ArticleLillys Mirikizumab Met Primary Endpoint and Key Secondary Endpoints in Phase...
INDIANAPOLISÂMay 21 2019ÂPRNewswire &8212; In an oral presentation from the Digestive Disease Week medical conference inÂSan Diego CaliforniaÂtodayÂEliÂLilly and CompanyNYSE LLY announced new...
View ArticleMirikizimab moved to Phase III after positive trial findings
Eli Lilly presents new data for their mirikizimab treatment for Crohns disease.The post
View ArticleTrivedi Global Inc. in Association with Sakina AnsariWilson Announces...
Forty percent decrease in expression of inflammatory biomarkers seen in the preclinical research.SILVER SPRING Md. PRWEB May 27 2019 Sakina A. AnsariWilson an evidencebased healer today announces...
View ArticleTrivedi Global Inc. and Sakina AnsariWilson Announce Research Results on the...
Overall immunity increased by over 250SILVER SPRING Md. PRWEB May 28 2019 Sakina A. AnsariWilson an evidencebased energy healer today announces research based on the impact of biofield energy treated...
View ArticleHealth Tip Understanding Crohn's Disease
Crohn's disease is a chronic condition that causes inflammation of the gastrointestinal tract. Though the exact cause is unknown both genetic and environmental factors may play a role.Crohn's disease...
View ArticleHow microbiome is disrupted during IBD Human Microbiome Project
A new study is the first to have observed the complex set of chemical and molecular events that disrupt the microbiome and trigger immune responses during flareups of inflammatory bowel diseases IBD...
View Article